UNSPSC 51285902: Cilastatin

This classification denotes a protease inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 141A6AMN38. European Medicines Agency schedules Cilastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06264MIG. Cilastatin generally arises in the molecular formula C16H26N2O5S.

The term CILASTATIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 38, no. 6, 1984, list 24.) CILASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O=C(N/C(=C\CCC)C(=O)O)C1C(C1)(C)C.

UNSPSC 51285902 Cilastatin, a Commodity code, nominally identifies a specific pharmaceutical active ingredient, but recent state and local solicitations tagged under this code address a broader scope of pharmaceutical procurement including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and medical-emergency supplies rather than cilastatin specifically. State and local governments are using this code to solicit quantities ranging from hundreds to tens of thousands of units annually through standard competitive bidding processes (IFB, RFP, RFI) with quarterly or ongoing delivery schedules. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), cities (Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local facilities in Minnesota and Oregon). The mix reflects both direct county and municipal procurement and cooperative-purchasing vehicles that aggregate demand across multiple jurisdictions.

Recent activity clusters in Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's IFB 26P00145 (posted March 25, 2026; due March 13, 2026) for 169 line items of medical and first aid supplies with an estimated contract value of $700,000 and an SLBE set-aside with 5 percent bid discount; and the Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) establishing multiple-award contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities. The Texas HHS RFI HHS0017013 (posted April 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription programs, indicating emerging interest in alternative distribution models beyond traditional wholesale channels.